

LCT accepts revised conditions for Diabecell trial in NZ

Cell-based therapeutics maker Living Cell Technologies said that the company has accepted a preliminary decision from the New Zealand Minister of Health, Mr Tony Ryall, to issue a new conditional authorization for its New Zealand phase I/IIa clinical trial of Diabecell for insulin dependent diabetes.

The Minister's letter states that "the proposed condition that would require (LCT) to amend the inclusion criteria of (LCT's) study to limit participation in the study to patients with brittle diabetes who suffer from significant metabolic instability is essential to ensure that the study complies with international guidelines, which require that participants obtain maximum benefit possible from their participation in the study".

The company said that the clinical protocol for the New Zealand diabetes trial has already been amended according to the proposed new conditions from the Minister.